Two-year interferon therapy with or without ribavirin in chronic delta hepatitis

Ege University Medical School Gastroenterology, Izmir, Turkey.
Antiviral therapy (Impact Factor: 3.02). 01/2005; 10(6):721-6.
Source: PubMed


The only beneficial agent for the treatment of chronic delta hepatitis (CDH) is interferon (IFN). However, there is no consensus on the best dosage or duration of IFN therapy. As ribavirin (RBV) increases the sustained response when added to IFN in chronic hepatitis C, probably because of its immunomodulatory effect, we aimed to investigate the efficacy of 2-year IFN treatment and whether RBV had any additive effect to IFN in CDH.
Patients (n = 31) with CDH were randomized with a 1:2 ratio as 10 patients (3 females/7 males, age 39 +/- 9) receiving IFN monotherapy (9 MU IFN-alpha2a three times weekly) and 21 patients (8 females/13 males, age 38 +/- 11) receiving IFN plus RBV for 2 years (IFN at the same dosage and RBV at 1000-1200 mg/day). Alanine transferase normalization and hepatitis delta virus (HDV) RNA negativity at the end of treatment and at the end of the follow-up period (at least 6 months following 2-year treatment) were primary endpoints of the study. In addition, virological response and biochemical response were determined separately.
Eight of 31 patients (25%) had cirrhosis in liver biopsies. Six patients from the IFN monotherapy group and 12 patients from the combination group had biochemical response. Five patients from the IFN monotherapy group and 11 patients from the combination group had virological response at the end of therapy. Two patients from the IFN group and five patients from the combination group had sustained biochemical response at the end of the follow-up period. Hepatitis B virus (HBV) activations with HBV DNA positivity were observed in two patients (one from the IFN monotherapy group, one from the combination group). Two patients (20%) in the IFN group and five patients (23.5%) in IFN plus RBV group remained as virological responders at the end of the follow-up period (P > 0.05). None of the patients with liver cirrhosis were responsive at the end of the follow-up period.
Almost 20% of the patients with CDH were responsive to 2-year IFN treatment at the end of the follow-up period and no additional effect of RBV was observed. Patients with advanced liver disease failed to respond to treatment.

Download full-text


Available from: Fulya Gunsar
  • Source
    • "Two hundred and forty-seven subjects were excluded from the analysis: 55 were untreated controls,[525355] 13 with undetermined virological response, 3 subjects for unknown HDV-RNA status at the start of therapy,[51] 19 for negative HDV-RNA prior to therapy,[5355] 28 for combination therapy with lamivudine,[1249] 43 for combination therapy with ribavirin[1348] 17 for monotherapy with lamivudine,[12] 31 for combination therapy with adefovir and 30 for adefovir monotherapy,[10] 8 patients for therapy with beta IFN.[53] Ultimately, a total of 227 patients were included in the analyses. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis D virus (HDV) infection is characterized by rapidly progressive liver disease with adverse prognosis in most patients. Although interferon is the only approved anti-HDV therapy, evidence regarding the efficacy and safety of its various regimens is either old or scattered. We searched systematically Medline, EMBASE, Scopus, the Cochrane Central Register of Controlled Trials, and ISI. The studies that evaluated treatment of chronic HDV infection with standard or pegylated interferon for at least 48 weeks were identified. Our inclusion criteria were positive anti-HDV antibody for 6 months and positive HDV-PCR at the start of study. We performed a meta-analysis for proportions using the arcsine transformation in random effects model. Sustained virological response (SVR) rate (negative Polymerase chain reaction (PCR) 6 months after cessation of therapy) was the end point of interest. Data were abstracted from 14 studies containing 227 chronic HDV-infected patients who received standard or pegylated interferon alpha-2a or -2b. Twenty-one and 30 patients of 71 and 156 who received standard or peginterferon, respectively, beyond 48 weeks achieved SVR. Pooled SVR rates were 29% [95% confidence interval (CI) 19; 41] and 19% (95% CI 10; 29), respectively. The rates of treatment withdrawal were similar. Our systematic review indicates that the literature lacks sufficient evidence to establish precise recommendations for treatment of HDV infection. Meta-analysis of these studies shows that standard dose of peginterferon is more effective than high dose of standard interferon as anti-HDV therapy.
    Full-text · Article · Oct 2012 · Journal of research in medical sciences
  • Source
    • "This seems to be the only treatment choice if the patients can tolerate the adverse effects of pegylated interferon therapy, and monitoring these patients for a sustained response is mandatory.Yurdaydin et al. reported sustained virological and biochemical response rates of 9% and 13%, respectively [9]. Gunsar et al. found virological and biochemical response rates at the end of therapy to be 50% and 60%, respectively [10]. Castelnau et al treated CHD patients with PEG-IFN-alpha 2b, 1.5 μg/kg weekly for 12 months, and reported an SVR of 43% and biochemical response rates of 57% [13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic delta hepatitis is the most severe form of viral hepatitis, for which interferon administration is the only available treatment. However, the efficacy of interferon treatment is affected by the dose and duration of treatment, and relapse rates are high. In this study, we sought to evaluate the efficacy of treatment with pegylated interferon and observe the relapse rates of delta hepatitis after treatment. Forty-six patients with chronic delta hepatitis were retrospectively studied between January 2002 and December 2010. Patients were evaluated for biochemical, virological, and histological responses. They were then followed-up for at least 1 year after discontinuation of the treatment. All the 46 patients in the study received PEG-IFN therapy. Of the 46 patients,25 were treated with PEG-IFN for 1 year and 21 were treated for 2 years. Sixteen patients(34.7%) showed a biochemical response, 27 (58.6%) showed a virological response, and 39 (84.7%) showed a histological response. Sustained virological and biochemical responseswere achieved in 41% and 47.8% of the patients, respectively. Sixteen (84.2%) patients of the 19 with high levels of hepatitis delta virus RNA (HDV RNA) (HDV RNAlevel > 1 × 105) and 10 (71.4%) of the 14 patients with high titers of hepatitis B surface antigen(HbsAg) (HbsAg > 102 IU/mL) at the beginning of the treatment showed relapse after treatment. We found no significant differences between 1-year and 2-year treatments.However, the relapse rate was lower in the 2-year treatment group. Higher HDV RNA and HbsAg levels before treatment were associated with higher relapse rates. Younger age was a significant factor in predicting response.
    Full-text · Article · Sep 2011 · Hepatitis Monthly
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis Delta is caused by coinfection with the hepatitis B virus and the hepatitis D virus and has to be considered as the most severe form of viral hepatitis. HDV infection may affect between 15 and 20 Million individuals worldwide with significant regional differences of HDV prevalence rates. The diagnosis of hepatitis delta in HBsAg-positive individuals is based on the detection of HDV antibodies and HDV RNA. Interferon alpha remains the only effective treatment as currently available nucleoside or nucleotide analogous are not effective against HDV. Recent trials showed that about 25 % of HDV-infected patients may clear HDV RNA by therapy with pegylated interferon alpha. Liver transplantation remains the only treatment option for the majority patients with advanced liver disease
    No preview · Article · Jun 2012 · Current Hepatitis Reports
Show more